References
- 1. SINGH N, ARMSTRONG DG, LIPSKY BA. Preventing foot ulcers in patients with diabetes. JAMA 2005; 293:217–28.
- 2. GIURATO L, MELONI M, IZZO V, et al. Osteomyelitis in diabetic foot: A comprehensive overview. World J. Diabetes 2017; 8:135–142.
- 3. LIPSKY BA, BERENDT AR, DEERY HG, et al. Diagnosis and Treatment of Diabetic Foot Infections. Clin. Infect. Dis. 2004; 39:885–910.
- 4. SCHNEIDER H-G, LAM QT. Procalcitonin for the clinical laboratory: a review. Pathology 2007; 39:383–90.
- 5. SCHUETZ P, CHRIST-CRAIN M, MÜLLER B. Procalcitonin and other biomarkers to improve assessment and antibiotic stewardship in infections--hope for hype? Swiss Med. Wkly. 2009; 139:318–26.
- 6. HAUSFATER P. Le dosage de la procalcitonine en pratique clinique chez l’adulte. La Rev. Médecine Interne 2007; 28:296–305.
- 7. DINH T, SNYDER G, VEVES A. Current techniques to detect foot infection in the diabetic patient. Int. J. Low. Extrem. Wounds 2010; 9:24–30.
- 8. GLAUDEMANS AWJM, UÇKAY I, LIPSKY BA. Challenges in diagnosing infection in the diabetic foot. Diabet. Med.2015; 32:748–59.
- 9. MASSARA M, DE CARIDI G, SERRA R, et al. The role of procalcitonin as a marker of diabetic foot ulcer infection. Int. Wound J. 2017;14:31–34.
- 10. PICHU S, PATEL BM, APPARSUNDARAM S, et al. Role of biomarkers in predicting diabetes complications with special reference to diabetic foot ulcers. Biomark. Med. 2017; 11:377–88.
- 11. VAN ASTEN SA, NICHOLS A, LA FONTAINE J, et al. The value of inflammatory markers to diagnose and monitor diabetic foot osteomyelitis. Int. Wound J. 2017; 14:40–45.
- 12. DELEVAUX I, ANDRE M, COLOMBIER M, et al. Can procalcitonin measurement help in differentiating between bacterial infection and other kinds of inflammatory processes? Ann. Rheum. Dis. 2003; 62:337–40.10.1136/ard.62.4.337
- 13. SIMON L, GAUVIN F, AMRE DK, et al. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin. Infect. Dis. 2004; 39:206–17.
- 14. CHRIST-CRAIN M, MÜLLER B. Procalcitonin in bacterial infections--hype, hope, more or less? Swiss Med. Wkly. 2005; 135:451–60.
- 15. ASSICOT M, GENDREL D, CARSIN H, et al. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet (London, England) 1993; 341:515–8.
- 16. AL-SHAMMAREE SW, ABU-ALKASEEM B, SALMAN I. Procalcitonin levels and other biochemical parameters in patients with or without diabetic foot complications. J. Res. Med. Sci.2017; 22:95.10.4103/jrms.JRMS_906_16
- 17. UMAPATHY D, DORNADULA S, RAJAGOPALAN A, et al. Potential of circulatory procalcitonin as a biomarker reflecting inflammation among South Indian diabetic foot ulcers. J. Vasc. Surg. 2017; pii: S0741-5214 (17) 31127-8 (epub ahead of print).
- 18. INGRAM JR, CAWLEY S, COULMAN E, et al. Levels of wound calprotectin and other inflammatory biomarkers aid in deciding which patients with a diabetic foot ulcer need antibiotic therapy (INDUCE study).Diabet. Med.2017 doi: 10.1111/dme.13431 (epub ahead of print).10.1111/dme.13431(epubaheadofprint)
- 19. YANG Q, CAO Y, FANG Y, et al. The influence of different debridement methods on the prognosis of elderly patients with diabetic foot ulcers and sepsis. Minerva Chir. 2017; 72:200–5.
- 20. PARK JH, SUH DH, KIM HJ, et al. Role of procalcitonin in infected diabetic foot ulcer. Diabetes Res. Clin. Pract.2017; 128:51–7.
- 21. REINER MM, KHOURY WE, CANALES MB, et al. Procalcitonin as a biomarker for predicting amputation level in lower extremity infections. J. Foot Ankle Surg. 2017; 56:484–91.10.1053/j.jfas.2017.01.014
- 22. KARAKAS A, ARSLAN E, CAKMAK T, et al. Predictive value of soluble CD14, Interleukin-6 and Procalcitonin for lower extremity amputation in people with diabetes with foot ulcers: A pilot study. Pakistan J. Med. Sci. 2014; 30:578–82.
- 23. JONAIDI JAFARI N, SAFAEE FIROUZABADI M, IZADI M, et al. Can procalcitonin be an accurate diagnostic marker for the classification of diabetic foot ulcers? Int. J. Endocrinol. Metab. 2014; 12:e13376.
- 24. MICHAIL M, JUDE E, LIASKOS C, et al. The performance of serum inflammatory markers for the diagnosis and follow-up of patients with osteomyelitis. Int. J. Low. Extrem. Wounds 2013; 12:94–9.
- 25. ALTAY FA, SENCAN İ, ŞENTÜRK GÇ, et al. Does treatment affect the levels of serum interleukin-6, interleukin-8 and procalcitonin in diabetic foot infection? A pilot study. J. Diabetes Complications 2012; 26:214–8.
- 26. MUTLUOĞLU M, UZUN G, İPCIOGLU OM, et al. Can procalcitonin predict bone infection in people with diabetes with infected foot ulcers? A pilot study. Diabetes Res. Clin. Pract. 2011; 94:53–6.10.1016/j.diabres.2011.05.023
- 27. JEANDROT A, RICHARD J-L, COMBESCURE C, et al. Serum procalcitonin and C-reactive protein concentrations to distinguish mildly infected from non-infected diabetic foot ulcers: a pilot study. Diabetologia 2008; 51:347–52.10.1007/s00125-007-0840-8
- 28. UZUN G, SOLMAZGUL E, CURUKSULU H, et al. Procalcitonin as a diagnostic aid in diabetic foot infections. Tohoku J. Exp. Med 2007; 213:305–12.
- 29. VICTORIA VAN ASTEN SA, GERADUS PETERS EJ, XI Y, et al. The role of biomarkers to diagnose diabetic foot osteomyelitis. A Meta-analysis. Curr. Diabetes Rev. 2016; 12:396–402.10.2174/1573399811666150713104401